Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
暂无分享,去创建一个
[1] T. Gambichler,et al. The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy , 2022, Journal of Cancer Research and Clinical Oncology.
[2] M. Del Vecchio,et al. The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy , 2021, Targeted Oncology.
[3] J. Theysohn,et al. Predictive Impact of The Inflammation-based Indices in Uveal Melanoma Liver Metastases Treated with Transarterial Hepatic Chemoperfusion , 2021, Radiology and oncology.
[4] Li Zhou,et al. Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials , 2021, Frontiers in Oncology.
[5] T. Mesti,et al. Adverse Events During Immunotherapy in Slovenian Patients with Metastatic Melanoma Reveal a Positive Correlation with Better Treatment Outcomes , 2021, Radiology and oncology.
[6] M. Fassan,et al. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. , 2021, European journal of cancer.
[7] Zhuoli Zhang,et al. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis , 2021, Frontiers in Oncology.
[8] G. Mariani,et al. The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab , 2021, Cancers.
[9] S. Tirumani,et al. Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors , 2021, JAMA network open.
[10] Xiao-yan Li,et al. Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade , 2021, Frontiers in Oncology.
[11] O. Dizdar,et al. PILE: a candidate prognostic score in cancer patients treated with immunotherapy , 2021, Clinical and Translational Oncology.
[12] R. Dummer,et al. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma , 2020, European journal of cancer.
[13] D. Bodet,et al. Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients , 2020, Clinical and Translational Oncology.
[14] V. Adamo,et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials , 2020, British Journal of Cancer.
[15] Versione,et al. Common Terminology Criteria for Adverse Events , 2020, Definitions.
[16] C. Keeble,et al. The neutrophil–lymphocyte ratio and locoregional melanoma: a multicentre cohort study , 2020, Cancer Immunology, Immunotherapy.
[17] T. Mesti,et al. Retrospective Analysis of Treatment-naive Slovenian Patients with Metastatic Melanoma Treated with Pembrolizumab – Real-world Experience , 2020, Radiology and oncology.
[18] D. Schadendorf,et al. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo , 2020, JAMA oncology.
[19] P. Ascierto,et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] Lei Zhan,et al. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. , 2019, American journal of cancer research.
[21] J. Larkin,et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. , 2019, The Lancet. Oncology.
[22] C. Mirili,et al. Clinical significance of prognostic nutritional index (PNI) in malignant melanoma , 2019, International Journal of Clinical Oncology.
[23] J. Wolchok,et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] D. Schadendorf,et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.
[25] J. Cebon,et al. Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma , 2018, Journal of surgical oncology.
[26] Wan-Hai Wang,et al. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis , 2018, Journal of Cancer.
[27] M. Marples,et al. Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study , 2018, Annals of Surgical Oncology.
[28] P. Queirolo,et al. Current status and perspectives in immunotherapy for metastatic melanoma , 2015, Oncotarget.
[29] C. Cui,et al. Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon , 2017, Translational oncology.
[30] Zi-Yu Chen,et al. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis , 2017, Oncotarget.
[31] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[32] E. Scarpi,et al. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer , 2016, Oncotarget.
[33] H. Muss,et al. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis. , 2015, Cancer treatment reviews.
[34] B. Zhou,et al. Inflammation fuels tumor progress and metastasis. , 2015, Current pharmaceutical design.
[35] D. Schadendorf,et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] I. Tannock,et al. Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[37] Berthold Lausen,et al. Maximally selected rank statistics , 1992 .